{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:12:28Z","timestamp":1737436348360,"version":"3.33.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Resistant hypertension (RH) is defined as uncontrolled blood pressure (BP) despite treatment with at least three or more antihypertensive agents. Compelling evidence has shown that such a population has a greater risk of cardiovascular events as well as mortality. Although mineralocorticoid receptor antagonists (MRAs) have been shown to be an effective fourth-line treatment for RH, a significant proportion of RH patients do not achieve their blood pressure target. Compound reserpine and triamterene tablets, a traditional Chinese quadruple single-pill combination, have been proven to have good antihypertensive effects as well as safety, and are promising effective antihypertensive drugs for treating RH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A randomized crossover clinical trial will be conducted to compare the efficacy and safety of compound reserpine and triamterene tablets treatment regimen (two tablets of olmesartan\/amlodipine (OA)\u2009+\u2009one tablet of compound reserpine and triamterene tablets) with those of a standard treatment regimen (two tablets of OA\u2009+\u2009indapamide 2.5\u00a0mg\u2009+\u2009spironolactone 20\u00a0mg) in patients with RH. Forty patients will be recruited and randomly assigned in a 1:1 ratio to 2 crossover groups. The two groups will receive different combination therapies for 6\u00a0weeks and will then switch to the other combination therapy for 6\u00a0weeks, with a 4-week wash-out. The primary outcome will be the reduction in average 24-h systolic blood pressure after 6\u00a0weeks of intervention between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>This study aimed to evaluate whether the compound reserpine and triamterene tablets treatment regimen (A\u2009+\u2009C\u2009+\u20090) results in a greater reduction in blood pressure in RH patients than the standard treatment regimen (A\u2009+\u2009C\u2009+\u2009D\u2009+\u2009spironolactone).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Chinese Clinical Trial Registry ChiCTR2400081878. Registered on March 14, 2024 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.chictr.org.cn\" ext-link-type=\"uri\">http:\/\/www.chictr.org.cn<\/jats:ext-link>).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-08719-8","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:45:30Z","timestamp":1737377130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The antihypertensive efficacy of a quadruple single-pill combination in patients with resistant hypertension: study protocol for a randomized, open-label, crossover trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Yuanyuan","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"8719_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"8719_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98\u2013105.","journal-title":"Heart"},{"key":"8719_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jch.13550","volume":"21","author":"SM Smith","year":"2019","unstructured":"Smith SM, Gurka MJ, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. J Clin Hypertens. 2019;21:825\u201334.","journal-title":"J Clin Hypertens"},{"key":"8719_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5334\/gh.1296","volume":"19","author":"OO Abiodun","year":"2024","unstructured":"Abiodun OO, Anya T, Chukwu JC, Adekanmbi V. Prevalence, risk factors and cardiovascular comorbidities of resistant hypertension among treated hypertensives in a Nigerian population. Glob Heart. 2024;19:17.","journal-title":"Glob Heart"},{"key":"8719_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","volume":"88","author":"JJ Sim","year":"2015","unstructured":"Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88:622\u201332.","journal-title":"Kidney Int"},{"key":"8719_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jch.14701","volume":"25","author":"G Bakris","year":"2023","unstructured":"Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023;25:737\u201347.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"8719_CR7","doi-asserted-by":"publisher","first-page":"1211199","DOI":"10.3389\/fcvm.2023.1211199","volume":"10","author":"MK Champaneria","year":"2023","unstructured":"Champaneria MK, Patel RS, Oroszi TL. When blood pressure refuses to budge: exploring the complexity of resistant hypertension. Front Cardiovasc Med. 2023;10:1211199.","journal-title":"Front Cardiovasc Med"},{"key":"8719_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ehjcvp\/pvz057","volume":"6","author":"LM Ruilope","year":"2020","unstructured":"Ruilope LM, Rodr\u00edguez-S\u00e1nchez E, Navarro-Garc\u00eda JA, Segura J, \u00d3rtiz A, Lucia A, et al. Resistant hypertension: new insights and therapeutic perspectives. Eur Heart J Cardiovasc Pharmacother. 2020;6:188\u201393.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"8719_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11906-023-01254-4","volume":"25","author":"G Grassi","year":"2023","unstructured":"Grassi G, Dell\u2019Oro R, Quarti-Trevano F, Vanoli J, Oparil S. sympathetic neural mechanisms in hypertension: recent insights. Curr Hypertens Rep. 2023;25:263\u201370.","journal-title":"Curr Hypertens Rep"},{"key":"8719_CR10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/jcm11051455","volume":"11","author":"G Bourque","year":"2022","unstructured":"Bourque G, Hiremath S. Rethinking resistant hypertension. J Clin Med. 2022;11:1455.","journal-title":"J Clin Med"},{"key":"8719_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159\u201364.","journal-title":"Arch Intern Med"},{"key":"8719_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8719_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/HYPERTENSIONAHA.119.13009","volume":"74","author":"R Dell\u2019Oro","year":"2019","unstructured":"Dell\u2019Oro R, Quarti-Trevano F, Seravalle G, Zanchettin F, Bertoli S, Airoldi F, et al. Sympathetic nerve traffic and arterial baroreflex function in apparent drug-resistant hypertension. Hypertension. 2019;74:903\u20139.","journal-title":"Hypertension"},{"key":"8719_CR14","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"8719_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","volume":"25","author":"C Wang","year":"2016","unstructured":"Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25:1021\u201330.","journal-title":"Heart Lung Circ"},{"key":"8719_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","volume":"21","author":"AA Manolis","year":"2019","unstructured":"Manolis AA, Manolis TA, Melita H, Manolis AS. Eplerenone versus spironolactone in resistant hypertension: an efficacy and\/or cost or just a men\u2019s issue? Curr Hypertens Rep. 2019;21:22.","journal-title":"Curr Hypertens Rep"},{"key":"8719_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"8719_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","volume":"73","author":"RM Carey","year":"2019","unstructured":"Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73:424\u201331.","journal-title":"Hypertension"},{"key":"8719_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41440-021-00845-5","volume":"45","author":"M Yoon","year":"2022","unstructured":"Yoon M, You SC, Oh J, Lee CJ, Lee S-H, Kang S-M, et al. Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements. Hypertens Res. 2022;45:1353\u201362.","journal-title":"Hypertens Res"},{"key":"8719_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/jch.14207","volume":"23","author":"L-X Hu","year":"2021","unstructured":"Hu L-X, Wang D, Liu H-L, Zhang Q-T, Sun D-S, Zhang L, et al. A double-blind, placebo-controlled trial on the antihypertensive treatment effect of a quadruple single-pill combination. J Clin Hypertens (Greenwich). 2021;23:815\u201322.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"8719_CR21","first-page":"e298","volume":"41","author":"NS Sun\/Ningling","year":"2023","unstructured":"Sun\/Ningling NS, Chen\/Yuanyuan YC, Wang\/Hongyi HW, Xi\/Yang YX. Evaluation on clinical application of low-dose traditional quadruple antihypertensive compound preparation in China. J Hypertens. 2023;41:e298.","journal-title":"J Hypertens"},{"key":"8719_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S2213-8587(15)00377-0","volume":"4","author":"MJ Brown","year":"2016","unstructured":"Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8719_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","volume":"71","author":"EM Krieger","year":"2018","unstructured":"Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the rehot randomized study (resistant hypertension optimal treatment). Hypertension. 2018;71:681\u201390.","journal-title":"Hypertension"},{"key":"8719_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/ajh\/hpaa042","volume":"33","author":"M Siddiqui","year":"2020","unstructured":"Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine substantially lowers blood pressure in patients with refractory hypertension: a proof-of-concept study. Am J Hypertens. 2020;33:741\u20137.","journal-title":"Am J Hypertens"},{"key":"8719_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","volume":"79","author":"NK Choudhry","year":"2022","unstructured":"Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2022;79:e1-14.","journal-title":"Hypertension"},{"key":"8719_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11886-020-01400-3","volume":"22","author":"SM Hamrahian","year":"2020","unstructured":"Hamrahian SM. Medication non-adherence: a major cause of resistant hypertension. Curr Cardiol Rep. 2020;22:133.","journal-title":"Curr Cardiol Rep"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08719-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:45:34Z","timestamp":1737377134000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08719-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8719"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08719-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial has been reviewed by the Biomedical Ethics Review Committee of West China Hospital of Sichuan University and registered in the China Clinical Trial Registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Copies of the informed consent forms are available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"All the authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"22"}}